Ciglitazone

C. Day; C. Bailey

doi:10.1016/B978-0-12-801238-3.97236-2

Ciglitazone

C. Day
, C. Bailey

Research output: Chapter in Book/Published conference output › Entry for encyclopedia/dictionary

Abstract

Ciglitazone was the first antidiabetic thiazolidinedione to be described in detail (Sohda et al., 1982). The thiazolidinediones (TZDs), also termed “glitazones”, activate the nuclear peroxisome proliferator-activated receptor-gamma (PPAR-gamma). Thiazolidinediones currently in clinical use for the treatment of type 2 diabetes are rosiglitazone (withdrawn in Europe in 2010) and pioglitazone. Another TZD, troglitazone, was withdrawn due to hepatotoxicity. Ciglitazone was not introduced into clinical use.

Original language	English
Title of host publication	Reference module in biomedical sciences
Publisher	Elsevier
ISBN (Print)	978-0-12-801238-3
DOIs	https://doi.org/10.1016/B978-0-12-801238-3.97236-2
Publication status	Published - 2016

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1016/B978-0-12-801238-3.97236-2

Cite this

@inbook{5833469ea8b34fd7b1a6ef6360257b82,

title = "Ciglitazone",

abstract = "Ciglitazone was the first antidiabetic thiazolidinedione to be described in detail (Sohda et al., 1982). The thiazolidinediones (TZDs), also termed “glitazones”, activate the nuclear peroxisome proliferator-activated receptor-gamma (PPAR-gamma). Thiazolidinediones currently in clinical use for the treatment of type 2 diabetes are rosiglitazone (withdrawn in Europe in 2010) and pioglitazone. Another TZD, troglitazone, was withdrawn due to hepatotoxicity. Ciglitazone was not introduced into clinical use.",

author = "C. Day and C. Bailey",

year = "2016",

doi = "10.1016/B978-0-12-801238-3.97236-2",

language = "English",

isbn = "978-0-12-801238-3",

booktitle = "Reference module in biomedical sciences",

publisher = "Elsevier",

address = "Netherlands",

}

TY - CHAP

T1 - Ciglitazone

AU - Day, C.

AU - Bailey, C.

PY - 2016

Y1 - 2016

N2 - Ciglitazone was the first antidiabetic thiazolidinedione to be described in detail (Sohda et al., 1982). The thiazolidinediones (TZDs), also termed “glitazones”, activate the nuclear peroxisome proliferator-activated receptor-gamma (PPAR-gamma). Thiazolidinediones currently in clinical use for the treatment of type 2 diabetes are rosiglitazone (withdrawn in Europe in 2010) and pioglitazone. Another TZD, troglitazone, was withdrawn due to hepatotoxicity. Ciglitazone was not introduced into clinical use.

AB - Ciglitazone was the first antidiabetic thiazolidinedione to be described in detail (Sohda et al., 1982). The thiazolidinediones (TZDs), also termed “glitazones”, activate the nuclear peroxisome proliferator-activated receptor-gamma (PPAR-gamma). Thiazolidinediones currently in clinical use for the treatment of type 2 diabetes are rosiglitazone (withdrawn in Europe in 2010) and pioglitazone. Another TZD, troglitazone, was withdrawn due to hepatotoxicity. Ciglitazone was not introduced into clinical use.

U2 - 10.1016/B978-0-12-801238-3.97236-2

DO - 10.1016/B978-0-12-801238-3.97236-2

M3 - Entry for encyclopedia/dictionary

SN - 978-0-12-801238-3

BT - Reference module in biomedical sciences

PB - Elsevier

ER -

Ciglitazone

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this